<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ATENOLOL</span><br/>(a-ten'oh-lole)<br/><span class="topboxtradename">Apo-Atenolol <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Tenormin<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic antagonist (sympatholytic, blocking agent)</span>; <span class="classification">antihypertensive agent</span><br/><b>Prototype: </b>Propranolol<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 100 mg tablets; 5 mg/10 mL vial</p>
<h1><a name="action">Actions</a></h1>
<p>In therapeutic doses, atenolol selectively blocks beta<sub>1</sub>-adrenergic receptors located chiefly in cardiac muscle. With large doses, preferential effect is lost and inhibition of beta<sub>2</sub>-adrenergic receptors may lead to increased airway resistance, especially in patients with asthma or COPD. Mechanisms for
         antihypertensive action include central effect leading to decreased sympathetic outflow to periphery, reduction in renin activity
         with consequent suppression of the renin-angiotensin-aldosterone system, and competitive inhibition of catecholamine binding
         at beta-adrenergic receptor sites.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces rate and force of cardiac contractions (negative inotropic action); cardiac output is reduced, as well as systolic
         and diastolic BP. Atenolol decreases peripheral vascular resistance both at rest and with exercise.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Management of hypertension as a single agent or concomitantly with other antihypertensive agents, especially a diuretic, and
         in treatment of stable angina pectoris, MI.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Antiarrhythmic, mitral valve prolapse, adjunct in treatment of pheochromocytoma and of thyrotoxicosis; and for vascular headache
         prophylaxis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sinus bradycardia, greater than first-degree AV heart block, uncompensated heart failure, cardiogenic shock, peripheral vascular
         disease, Raynaud's disease, hypotension; abrupt discontinuation, pulmonary edema. Safety during pregnancy (category D), or
         lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertensive patients with CHF controlled by digitalis and diuretics, vasospastic angina (Prinzmetal's angina); asthma, bronchitis,
         emphysema, and COPD; major depression; diabetes mellitus; impaired renal function, dialysis; myasthenia gravis; pheochromocytoma,
         hyperthyroidism, thyrotoxicosis; older adults.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension, Angina</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2550 mg/d, may increase to 100 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.81.5 mg/kg/d (max: 2 mg/kg/d)<br/><br/><span class="indicationtitle">MI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 10 min after second IV dose, start 50 mg/d <span class="rdroute">IV</span> 5 mg q5min times 2 doses, then switch to PO<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Crush tablets, if necessary, before administration and give with fluid of patient's choice.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Use undiluted or diluted in 1050 mL of NS, D5W, D5/NS, D5/0.45NS, or 0.45NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 5 min.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store in tightly closed, light-resistant container at 15°30° C (59°86° F) unless otherwise
            directed.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, vertigo, light-headedness, syncope, fatigue or weakness, lethargy, drowsiness, insomnia, mental changes, depression. <span class="typehead">CV:</span>
<span class="speceff-common">Bradycardia, hypotension, CHF,</span> cold extremities, leg pains, dysrhythmias. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea. <span class="typehead"> Respiratory:</span> Pulmonary edema, dyspnea, <span class="speceff-life">bronchospasm</span>. <span class="typehead">Other:</span> May mask symptoms of hypoglycemia; decreased sexual ability. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Atropine</b> and other <span class="classification">anticholinergics</span> may increase atenolol absorption from GI tract; <span class="classification">nsaids</span> may decrease hypotensive effects; may mask symptoms of a hypoglycemic reaction induced by <b>insulin,</b>
<span class="classification">sulfonylureas</span>; may increase <b>lidocaine</b> levels and toxicity; pharmacologic and toxic effects of both atenolol and <b>verapamil</b> are increased. <b>Prazosin,</b>
<b>terazocin</b> may increase severe hypotensive response to first dose of atenolol. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 50% of PO dose absorbed. <span class="typehead">Peak:</span> 24 h PO; 5 min IV. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> Does not readily cross bloodbrain barrier. <span class="typehead">Metabolism:</span> No hepatic metabolism. <span class="typehead">Elimination:</span> 4050% excreted in urine; 5060% excreted in feces. <span class="typehead">Half-Life:</span> 67 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Neonates born to mothers who are receiving atenolol at parturition or breastfeeding may be at risk for hypoglycemia.</li>
<li>Check apical pulse before giving oral drug, especially in patients receiving digitalis (both drugs slow AV conduction). If
            below 60 bpm (or other ordered parameter), withhold dose and consult physician.
         </li>
<li>Monitor apical pulse, BP, respirations, and peripheral circulation throughout dosage adjustment period. Consult physician
            for acceptable parameters.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Adhere rigidly to dose regimen. Sudden discontinuation of drug can exacerbate angina and precipitate tachycardia or MI in
            patients with coronary artery disease, and thyroid storm in patients with hyperthyroidism.
         </li>
<li>Make position changes slowly and in stages, particularly from recumbent to upright posture.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>